       Document 0470
 DOCN  M9630470
 TI    Self-sufficiency and blood transmitted diseases.
 DT    9603
 AU    Glomstein A; Institute for Haemophilia, Oslo, Norway.
 SO    Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S23-6. Unique Identifier :
       AIDSLINE MED/96076194
 AB    The Council of Europe and the EEC Council of Ministers have strongly
       promoted self-sufficiency for plasma products on the basis of voluntary
       non-remunerated donors. Several European countries have a programme of
       self-sufficiency with plasma products, either with national
       fractionation plants (e.g. Belgium, Finland) or based on contract
       fractionation (e.g. Norway, Slovenia). Advantages of national
       self-sufficiency includes epidemiological factors, economical factors
       and also ethical and moral issues. Self-sufficiency is one of the basic
       conditions for reducing the hazard of transmission of infectious
       diseases. Norway has been self-sufficient with coagulation factors since
       1981. Price mechanisms and market forces have been important factors in
       ensuring the necessary plasma volume, and fractionation methods
       rendering high yields of factor VIII are initially preferred. This
       policy has resulted in a low prevalence of antibodies against human
       immunodeficiency virus (6%), hepatitis B virus (28%) and hepatitis C
       virus (41%). No Norwegian haemophiliacs have been infected with
       hepatitis A through FVIII concentrates.
 DE    *Blood Banks  *Blood Donors  Blood Transfusion/*ADVERSE EFFECTS
       European Economic Community  Human  Norway  Virus Diseases/*TRANSMISSION
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

